Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial
Participants with prediabetes are at a high risk of developing type 2 diabetes (T2D). Recent studies have suggested that blocking the receptor activator of nuclear factor- κB ligand (RANKL) may improve glucose ... (Source: Trials)
Source: Trials - December 18, 2023 Category: General Medicine Authors: Yilin Wang, Yu Jiang, Jia Li, Xisheng Lin, Yan Luo, Shuhuai Tan, Haohan Yang, Zefu Gao, Xiang Cui, Pengbin Yin, Dan Kong, Yuan Gao, Yu Cheng, Licheng Zhang, Peifu Tang and Houchen Lyu Tags: Study protocol Source Type: research
Denosumab and Mortality in a Real ‐World Setting: A Comparative Study
This study examined the association between Dmab and all-cause mortality compared with no treatment in subjects with a fracture and BPs in subjects without a fracture. The study population was from the Sax Institute's 45 and Up Study (n = 267,357), a prospective population-based cohort with questionnaire data linked to hospital admissions (Admitted Patients Data Collection [APDC] data were linked by the Centre for Health Record Linkage), medication records (Pharmaceutical Benefits Scheme [PBS] provided by Services Australia), and stored securely (secure data access was provided through the Sax Institute's Secure Unifie...
Source: Journal of Bone and Mineral Research - December 16, 2023 Category: Orthopaedics Authors: Dunia Alarkawi,
Thach Tran,
Weiwen Chen,
Lyn M March,
Fiona M Blyth,
Robert D Blank,
Dana Bliuc,
Jacqueline R Center Tags: Research Article Source Type: research
Efficacy of denosumab in the treatment of hypercalcemic renal dysfunction in sarcoidosis: a case report
AbstractA 70-year-old female patient was admitted for close examination and treatment of hypercalcemia (corrected serum calcium levels: 3.04 mmol/L) and renal dysfunction (serum creatinine levels: 254.59 µmol/L). The patient had a history of sarcoidosis, diagnosed based on epithelioid cell granulomas in subcutaneous nodule biopsies, uveitis, and bilateral hilar lymphadenopathy, which had spontaneously remitted 10 years before admiss ion. Because the patient was diagnosed with hypercalcemia associated with recurrent sarcoidosis, prednisone (20 mg/day) was initiated, and its dose was tapered following the decrease in s...
Source: Osteoporosis International - December 16, 2023 Category: Orthopaedics Source Type: research
Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study
ConclusionThis large-scale, multicenter chart review provides clinically relevant insights into the profiles of patients initiating romosozumab, effectiveness of real-world romosozumab use, and sequential therapy in Japanese patients at high risk of fracture. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - December 12, 2023 Category: Orthopaedics Source Type: research
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors
DISCUSSION: Both alendronate and denosumab significantly contributed to preventing secondary osteoporosis in early BC patients with low BMD undergoing AIs, mostly at the lumbar spine level. Moreover, alendronate seemed to significantly impact pain control in such patients further supporting alendronate as a cost-effective option in this frail setting, although BMAs particularities should be carefully considered on an individual basis according to specific clinical contexts.PMID:38075057 | PMC:PMC10702721 | DOI:10.3389/fendo.2023.1297950 (Source: Cancer Control)
Source: Cancer Control - December 11, 2023 Category: Cancer & Oncology Authors: Antonio Galvano Valerio Gristina Dalila Scaturro Tancredi Didier Bazan Russo Sofia Tomasello Fabio Vitagliani Federica Carit à Maria La Mantia Fabio Fulfaro Viviana Bazan Giulia Letizia Mauro Antonio Russo Source Type: research
Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab
This study is the first report to show that teriparatide combined with denosumab can be used to treat Gorham-Stout syndrome. (Source: Osteoporosis International)
Source: Osteoporosis International - December 8, 2023 Category: Orthopaedics Source Type: research
Does denosumab exert a protective effect against COVID-19? Results of a large cohort study
ConclusionOur study confirms that denosumab may be safely continued in COVID-19 patients. RANK/RANKL inhibition seems associated with a reduced incidence of symptomatic COVID-19, particularly among the elderly. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 7, 2023 Category: Endocrinology Source Type: research
Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document
CONCLUSIONS: Denosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and in some cases is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimise risks.PMID:38041865 | DOI:10.1210/clinem/dgad657 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 2, 2023 Category: Endocrinology Authors: Joel A Vanderniet Vivian Szymczuk Wolfgang H ögler Signe S Beck-Nielsen Suma Uday Nadia Merchant Janet L Crane Leanne M Ward Alison M Boyce Craig F Munns Source Type: research
Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document
CONCLUSIONS: Denosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and in some cases is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimise risks.PMID:38041865 | DOI:10.1210/clinem/dgad657 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 2, 2023 Category: Endocrinology Authors: Joel A Vanderniet Vivian Szymczuk Wolfgang H ögler Signe S Beck-Nielsen Suma Uday Nadia Merchant Janet L Crane Leanne M Ward Alison M Boyce Craig F Munns Source Type: research
Denosumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
The effect of denosumab treatment on muscle strength and muscle mass in patients followed up with osteoporosis
Rationale: We aimed to investigate the effect of denosumab on muscle mass in patients with osteoporosis and under denosumab treatment during the 6-month period. (Source: Clinical Nutrition ESPEN)
Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: Z. Şahiner, M. Güner, S. Ceylan, A. Okyar Baş, M. Hafızoğlu, D. Karaduman, C. Atbaş, Y. Polat Özer, C. Balcı, B.B. Doğu, M. Cankurtaran, M.G. Halil Source Type: research
Denosumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia
ConclusionFrom the perspective of a Malaysian MOH healthcare provider, moderately increasing uptake of denosumab would have a minimal additional budget impact, partially offset by savings in fracture treatment costs. Increasing the use of denosumab appears affordable to reduce the economic burden of osteoporosis in Malaysia. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - November 30, 2023 Category: Orthopaedics Source Type: research
